72 related articles for article (PubMed ID: 11067745)
1. A high-throughput glow-type aequorin assay for measuring receptor-mediated changes in intracellular calcium levels.
George SE; Schaeffer MT; Cully D; Beer MS; McAllister G
Anal Biochem; 2000 Nov; 286(2):231-7. PubMed ID: 11067745
[TBL] [Abstract][Full Text] [Related]
2. Measurement of intracellular calcium using bioluminescent aequorin expressed in human cells.
Sheu YA; Kricka LJ; Pritchett DB
Anal Biochem; 1993 Mar; 209(2):343-7. PubMed ID: 8470808
[TBL] [Abstract][Full Text] [Related]
3. Aequorin luminescence-based assay for 5-hydroxytryptamine (serotonin) type 3 receptor characterization.
Walstab J; Combrink S; Brüss M; Göthert M; Niesler B; Bönisch H
Anal Biochem; 2007 Sep; 368(2):185-92. PubMed ID: 17617370
[TBL] [Abstract][Full Text] [Related]
4. Use of bioluminescent aequorin for the pharmacological characterization of 5HT receptors.
Schaeffer MT; Cully D; Chou M; Liu J; Van der Ploeg LH; Fong TM
J Recept Signal Transduct Res; 1999 Nov; 19(6):927-38. PubMed ID: 10533981
[TBL] [Abstract][Full Text] [Related]
5. An automated aequorin luminescence-based functional calcium assay for G-protein-coupled receptors.
Ungrin MD; Singh LM; Stocco R; Sas DE; Abramovitz M
Anal Biochem; 1999 Jul; 272(1):34-42. PubMed ID: 10405290
[TBL] [Abstract][Full Text] [Related]
6. Recombinant aequorin as a reporter for receptor-mediated changes of intracellular Ca2+ -levels in Drosophila S2 cells.
Torfs H; Poels J; Detheux M; Dupriez V; Van Loy T; Vercammen L; Vassart G; Parmentier M; Vanden Broeck J
Invert Neurosci; 2002 Apr; 4(3):119-24. PubMed ID: 12488971
[TBL] [Abstract][Full Text] [Related]
7. Comparison of antagonist activity of spantide family at human neurokinin receptors measured by aequorin luminescence-based functional calcium assay.
Janecka A; Poels J; Fichna J; Studzian K; Vanden Broeck J
Regul Pept; 2005 Nov; 131(1-3):23-8. PubMed ID: 15990182
[TBL] [Abstract][Full Text] [Related]
8. Identification of two serine residues essential for agonist-induced 5-HT2A receptor desensitization.
Gray JA; Compton-Toth BA; Roth BL
Biochemistry; 2003 Sep; 42(36):10853-62. PubMed ID: 12962510
[TBL] [Abstract][Full Text] [Related]
9. Mu-opioid receptor ligands lack receptor subtype selectivity in the aequorin luminescence-based calcium assay.
Fichna J; Staniszewska R; Poels J; Vanden Broeck J; Janecka A
Chem Biol Drug Des; 2007 Sep; 70(3):247-53. PubMed ID: 17718719
[TBL] [Abstract][Full Text] [Related]
10. Naturally occurring variants in the HTR3B gene significantly alter properties of human heteromeric 5-hydroxytryptamine-3A/B receptors.
Walstab J; Hammer C; Bönisch H; Rappold G; Niesler B
Pharmacogenet Genomics; 2008 Sep; 18(9):793-802. PubMed ID: 18698232
[TBL] [Abstract][Full Text] [Related]
11. [D-1-Nal4]endomorphin-2 is a potent micro-opioid receptor antagonist in the aequorin luminescence-based calcium assay.
Fichna J; Piestrzeniewicz M; Gach K; Poels J; Burgeon E; Vanden Broeck J; Janecka A
Life Sci; 2006 Aug; 79(11):1094-9. PubMed ID: 16624333
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of 5-HT(2) receptors in prefrontal pyramidal neurons inhibits Ca(v)1.2 L type Ca(2+) currents via a PLCbeta/IP3/calcineurin signaling cascade.
Day M; Olson PA; Platzer J; Striessnig J; Surmeier DJ
J Neurophysiol; 2002 May; 87(5):2490-504. PubMed ID: 11976386
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of cell lines for high-throughput screening of human neuromedin U receptor subtype 2 specific agonists using a luciferase reporter gene assay.
Li X; Shen F; Zhang Y; Zhu J; Huang L; Shi Q
Eur J Pharm Biopharm; 2007 Aug; 67(1):284-92. PubMed ID: 17337170
[TBL] [Abstract][Full Text] [Related]
14. Decreased agonist, but not antagonist, binding to the naturally occurring Thr92Lys variant of the h5-HT7(a) receptor.
Brüss M; Kiel S; Bönisch H; Kostanian A; Göthert M
Neurochem Int; 2005 Aug; 47(3):196-203. PubMed ID: 15896881
[TBL] [Abstract][Full Text] [Related]
15. Stable expression of a synthetic gene for the human motilin receptor: use in an aequorin-based receptor activation assay.
Carreras CW; Siani MA; Santi DV; Dillon SB
Anal Biochem; 2002 Jan; 300(2):146-51. PubMed ID: 11779105
[TBL] [Abstract][Full Text] [Related]
16. Differences in rapid desensitization of 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptor-mediated phospholipase C activation.
Berg KA; Stout BD; Maayani S; Clarke WP
J Pharmacol Exp Ther; 2001 Nov; 299(2):593-602. PubMed ID: 11602671
[TBL] [Abstract][Full Text] [Related]
17. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
Newman-Tancredi A; Cussac D; Quentric Y; Touzard M; Verrièle L; Carpentier N; Millan MJ
J Pharmacol Exp Ther; 2002 Nov; 303(2):815-22. PubMed ID: 12388668
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the contractile 5-hydroxytryptamine receptor in the renal artery of the normotensive rat.
Watts SW; Thompson JM
J Pharmacol Exp Ther; 2004 Apr; 309(1):165-72. PubMed ID: 14724222
[TBL] [Abstract][Full Text] [Related]
19. 5-hydroxyindalpine, an agonist at the putative 5-HT receptor, has no activity on human recombinant monoamine receptors but accelerates distension-induced peristalsis in mouse isolated colon.
Mitchell NA; Pepperell E; Ociepka S; Brown JD; Witherington J; Tuladhar B; Sanger GJ; Lee K; Cellek S
Neurogastroenterol Motil; 2009 Jul; 21(7):760-e48. PubMed ID: 19309442
[TBL] [Abstract][Full Text] [Related]
20. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics.
Weiner DM; Burstein ES; Nash N; Croston GE; Currier EA; Vanover KE; Harvey SC; Donohue E; Hansen HC; Andersson CM; Spalding TA; Gibson DF; Krebs-Thomson K; Powell SB; Geyer MA; Hacksell U; Brann MR
J Pharmacol Exp Ther; 2001 Oct; 299(1):268-76. PubMed ID: 11561089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
